Sign Up to like & get
recommendations!
0
Published in 2017 at "British Journal of Surgery"
DOI: 10.1002/bjs.10550
Abstract: According to some guidelines for the management of gastric cancer, adjuvant chemotherapy is recommended for patients with pT3–4 or node‐positive disease. The aim of this study was to define low‐ and high‐risk groups in terms…
read more here.
Keywords:
nomogram selecting;
patients chemotherapy;
chemotherapy gastrectomy;
validation nomogram ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Hepatology"
DOI: 10.1002/hep.30278
Abstract: Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is…
read more here.
Keywords:
hepatocellular carcinoma;
milan criteria;
patients hcc;
liver transplantation ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Advances in Radiation Oncology"
DOI: 10.1016/j.adro.2022.100903
Abstract: Purpose Selecting patients who will benefit from proton therapy is laborious and subjective. We demonstrate a novel automated solution for creating high-quality knowledge-based plans (KBPs) using proton and photon beams to identify patients for proton…
read more here.
Keywords:
proton therapy;
knowledge based;
patients proton;
based normal ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Gastroenterology Report"
DOI: 10.1093/gastro/gox030
Abstract: Abstract Objective To explore the performance of a protocol combining fecal immunochemical test (FIT) and a high-risk factor questionnaire (HRFQ) for selecting patients requiring colonoscopy as part of a population-based colorectal cancer (CRC) screening program…
read more here.
Keywords:
hrfq;
patients requiring;
fecal immunochemical;
colonoscopy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "OncoTargets and Therapy"
DOI: 10.2147/ott.s318332
Abstract: Abstract Erdafitinib received accelerated approval on April 12, 2019, for patients with metastatic or locally advanced urothelial carcinoma with susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations and who have progressed during…
read more here.
Keywords:
evidence selecting;
clinical evidence;
advanced urothelial;
urothelial carcinoma ... See more keywords